Several therapeutic agents have been investigated for treatment of novel Coronavirus‐2019 (nCOV‐2019). We conducted a systematic review and meta‐analysis to assess the efficacy of various treatment modalities in nCOV‐2019 patients.
A literature search was conducted before 29 June 2020 in PubMed, Google Scholar, Cochrane library databases. A fixed‐effect model was applied if I2 <50%, else results were combined using random‐effect model. Risk Ratio (RR) or Standardized Mean Difference (SMD) along‐with 95% Confidence Interval (95%CI) were used to pool the results. Between‐study heterogeneity was explored using influence and sensitivity analyses and publication bias was assessed using funnel plots. Entire statistical analysis was conducted in R version 3.6.2.
Fifty studies involving 15 in‐vitro and 35 clinical studies including 9170 nCOV‐2019 patients were included. Lopinavir‐Ritonavir was significantly associated with shorter mean time to clinical recovery (SMD ‐0.32; 95%CI ‐0.57 to ‐0.06), Remdesivir was significantly associated with better overall clinical recovery (RR 1.17; 95%CI 1.07 to 1.29) and Tocilizumab was associated with less all‐cause mortality (RR 0.38; 95%CI 0.16 to 0.93). Hydroxychloroquine was associated with longer time to clinical recovery and less overall clinical recovery. It additionally had higher all‐cause mortality and more total adverse…
This News From Feed news.google title “Efficacy of various treatment modalities for nCOV‐2019: a systematic review and meta‐analysis – Wiley”
geico insurance,instant auto insurance quote,get auto insurance online,purchase auto insurance online,auto insurance quotes online,farmers insurance,farm insurance,a car insurance